p.118 抽出テキスト

976. Nakayama M, Tanaka N, Sakoda K, Hokama Y, Hoshino K, Kimura Y, et al. Papaverine-induced polymorphic ventricular tachycardia during coronary flow reserve study of patients with moderate coronary artery disease—analysis of ECG data. Circ J 2015;79:530–6. https://doi.org/10.1253/circj.CJ-14-1118 977. Beltrame JF, Tavella R, Jones D, Zeitz C. Management of ischaemia with nonobstructive coronary arteries (INOCA). BMJ 2021;375:e060602. https://doi.org/10. 1136/bmj-2021-060602 978. Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al. 1-Year outcomes of angina management guided by invasive coronary function testing (CorMicA). JACC Cardiovasc Interv 2020;13:33–45. https://doi.org/10.1016/j.jcin.2019. 11.001 979. Kaski JC, Crea F, Gersh BJ, Camici PG. Reappraisal of ischemic heart disease. Circulation 2018;138:1463–80. https://doi.org/10.1161/CIRCULATIONAHA.118.031373 980. Sinha A, Rahman H, Douiri A, Demir OM, De Silva K, Clapp B, et al. ChaMP-CMD: a phenotype-blinded, randomized controlled, cross-over trial. Circulation 2024;149: 36–47. https://doi.org/10.1161/CIRCULATIONAHA.123.066680 981. Jansen TPJ, Konst RE, de Vos A, Paradies V, Teerenstra S, van den Oord SCH, et al. Efficacy of diltiazem to improve coronary vasomotor dysfunction in ANOCA: the EDIT-CMD randomized clinical trial. JACC Cardiovasc Imaging 2022;15:1473–84. https://doi.org/10.1016/j.jcmg.2022.03.012 982. Guarini G, Huqi A, Morrone D, Capozza P, Todiere G, Marzilli M. Pharmacological approaches to coronary microvascular dysfunction. Pharmacol Ther 2014;144:283–302. https://doi.org/10.1016/j.pharmthera.2014.06.008 983. Cattaneo M, Porretta AP, Gallino A. Ranolazine: drug overview and possible role in primary microvascular angina management. Int J Cardiol 2015;181:376–81. https:// doi.org/10.1016/j.ijcard.2014.12.055 984. Imran TF, Malapero R, Qavi AH, Hasan Z, de la Torre B, Patel YR, et al. Efficacy of spinal cord stimulation as an adjunct therapy for chronic refractory angina pectoris. Int J Cardiol 2017;227:535–42. https://doi.org/10.1016/j.ijcard.2016.10.105 985. Lee BK, Lim HS, Fearon WF, Yong AS, Yamada R, Tanaka S, et al. Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation 2015;131:1054–60. https://doi.org/10.1161/CIRCULATIONAHA.114.012636 986. Shufelt CL, Thomson LE, Goykhman P, Agarwal M, Mehta PK, Sedlak T, et al. Cardiac magnetic resonance imaging myocardial perfusion reserve index assessment in women with microvascular coronary dysfunction and reference controls. Cardiovasc Diagn Ther 2013;3:153–60. https://doi.org/10.3978/j.issn.2223-3652.2013.08.02 987. Echavarria-Pinto M, Escaned J, Macias E, Medina M, Gonzalo N, Petraco R, et al. Disturbed coronary hemodynamics in vessels with intermediate stenoses evaluated with fractional flow reserve: a combined analysis of epicardial and microcirculatory involvement in ischemic heart disease. Circulation 2013;128:2557–66. https://doi.org/10. 1161/CIRCULATIONAHA.112.001345 988. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol 1994;23:652–7. https://doi.org/10.1016/0735- 1097(94)90750-1 989. Erdamar H, Sen N, Tavil Y, Yazc HU, Turfan M, Poyraz F, et al. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis 2009;20:238–44. https://doi.org/10.1097/mca. 0b013e32830936bb 990. Kayaalti F, Kalay N, Basar E, Mavili E, Duran M, Ozdogru I, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels 2010;25: 92–6. https://doi.org/10.1007/s00380-009-1170-1 991. Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, Tabatznik B, et al. Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med 1980; 302:1269–73. https://doi.org/10.1056/nejm198006053022301 992. Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for Prinzmetal’s variant angina. N Engl J Med 1981;304:862–6. https://doi.org/10.1056/ nejm198104093041502 993. Ginsburg R, Lamb IH, Schroeder JS, Hu M, Harrison DC. Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982;103:44–8. https://doi.org/10.1016/ 0002-8703(82)90527-0 994. Pesola A, Lauro A, Gallo R, Madeo A, Cosentino G. Efficacy of diltiazem in variant angina. Results of a double-blind crossover study in CCU by Holter monitoring. The possible occurrence of a withdrawal syndrome. G Ital Cardiol 1987;17:329–39. 995. Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, et al. Randomized placebo-controlled trial of amlodipine in vasospastic angina. Amlodipine Study 160 Group. J Am Coll Cardiol 1993;21:1365–70. https://doi.org/10.1016/0735–1097(93) 90310-w 996. Oikawa Y, Matsuno S, Yajima J, Nakamura M, Ono T, Ishiwata S, et al. Effects of treatment with once-daily nifedipine CR and twice-daily benidipine on prevention of symptomatic attacks in patients with coronary spastic angina pectoris—Adalat Trial vs Coniel in Tokyo against Coronary Spastic Angina (ATTACK CSA). J Cardiol 2010; 55:238–47. https://doi.org/10.1016/j.jjcc.2009.11.005 997. Aschermann M, Bultas J, Karetová D, Kölbel F, Kozáková M, Simper D. Randomized double-blind comparison of isosorbide dinitrate and nifedipine in variant angina pectoris. Am J Cardiol 1990;65:J46–9. https://doi.org/10.1016/0002-9149(90)91312-t 998. Seitz A, Feenstra R, Konst RE, Martínez Pereyra V, Beck S, Beijk MAM, et al. Acetylcholine rechallenge: a first step toward tailored treatment in patients with coronary artery spasm. JACC Cardiovasc Interv 2022;15:65–75. https://doi.org/10.1016/j. jcin.2021.10.003 999. Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, et al. Prognostic effects of calcium channel blockers in patients with vasospastic angina—a meta-analysis. Circ J 2010;74:1943–50. https://doi.org/10.1253/circj.cj-10-0292 1000. Winniford MD, Gabliani G, Johnson SM, Mauritson DR, Fulton KL, Hillis LD. Concomitant calcium antagonist plus isosorbide dinitrate therapy for markedly active variant angina. Am Heart J 1984;108:1269–73. https://doi.org/10.1016/0002-8703(84) 90752-x 1001. Gu SZ, Beska B, Chan D, Neely D, Batty JA, Adams-Hall J, et al. Cognitive decline in older patients with non-ST elevation acute coronary syndrome. J Am Heart Assoc 2019;8:e011218. https://doi.org/10.1161/jaha.118.011218 1002. Beska B, Coakley D, MacGowan G, Adams-Hall J, Wilkinson C, Kunadian V. Frailty and quality of life after invasive management for non-ST elevation acute coronary syndrome. Heart 2022;108:203–11. https://doi.org/10.1136/heartjnl-2021-319064 1003. Beska B, Mills GB, Ratcovich H, Wilkinson C, Damluji AA, Kunadian V. Impact of multimorbidity on long-term outcomes in older adults with non-ST elevation acute coronary syndrome in the North East of England: a multi-centre cohort study of patients undergoing invasive care. BMJ Open 2022;12:e061830. https://doi.org/10.1136/ bmjopen-2022-061830 1004. Mills GB, Ratcovich H, Adams-Hall J, Beska B, Kirkup E, Raharjo DE, et al. Is the contemporary care of the older persons with acute coronary syndrome evidence-based? Eur Heart J Open 2022;2:oeab044. https://doi.org/10.1093/ehjopen/oeab044 1005. Ratcovich H, Beska B, Mills G, Holmvang L, Adams-Hall J, Stevenson H, et al. Five-year clinical outcomes in patients with frailty aged ≥75 years with non-ST elevation acute coronary syndrome undergoing invasive management. Eur Heart J Open 2022;2: oeac035. https://doi.org/10.1093/ehjopen/oeac035 1006. Sinclair H, Batty JA, Qiu W, Kunadian V. Engaging older patients in cardiovascular research: observational analysis of the ICON-1 study. Open Heart 2016;3:e000436. https://doi.org/10.1136/openhrt-2016-000436 1007. Mas-Llado C, Gonzalez-Del-Hoyo M, Siquier-Padilla J, Blaya-Peña L, Coughlan JJ, García de la Villa B, et al. Representativeness in randomised clinical trials supporting acute coronary syndrome guidelines. Eur Heart J Qual Care Clin Outcomes 2023;9: 796–805. https://doi.org/10.1093/ehjqcco/qcad007 1008. Rossello X, Ferreira JP, Caimari F, Lamiral Z, Sharma A, Mehta C, et al. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. Clin Res Cardiol 2021;110:1612–24. https://doi. org/10.1007/s00392-021-01859-2 1009. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet 2018;391:41–50. https://doi.org/10.1016/S0140-6736(17)32713-7 1010. Chung K, Wilkinson C, Veerasamy M, Kunadian V. Frailty scores and their utility in older patients with cardiovascular disease. Interv Cardiol 2021;16:e05. https://doi. org/10.15420/icr.2020.18 1011. Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, et al. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet 2021;397:2385–438. https://doi.org/10.1016/s0140-6736(21)00684-x 1012. Gaudino M, Di Franco A, Cao D, Giustino G, Bairey Merz CN, Fremes SE, et al. Sex-related outcomes of medical, percutaneous, and surgical interventions for coronary artery disease: JACC focus seminar 3/7. J Am Coll Cardiol 2022;79:1407–25. https://doi.org/10.1016/j.jacc.2021.07.066 1013. Jackson J, Alkhalil M, Ratcovich H, Wilkinson C, Mehran R, Kunadian V. Evidence base for the management of women with non-ST elevation acute coronary syndrome. Heart 2022;108:1682–9. https://doi.org/10.1136/heartjnl-2021-320533 1014. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. J Am Coll Cardiol 2014;63:1815–22. https:// doi.org/10.1016/j.jacc.2014.02.529 1015. Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42:967–84. https://doi.org/10.1093/ eurheartj/ehaa1044 1016. Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health 2019;4:e553–64. https://doi.org/10.1016/s2468- 2667(19)30155-0 1017. Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation 2021;143:e902–16. https://doi.org/10. 1161/cir.0000000000000961 Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026